News

Alzheimer's drug adoption in US slowed by doctors' skepticism

Lyn Castellano receives infusions of Eisai and Biogen's Alzheimer's drug Leqembi, alongside her service dog Jazmin at the Missouri Baptist Medical Center Infusion Center in St. Louis, Missouri, U.S. October 30, 2023. Joe Castellano/Handout via REUTERS
Lyn Castellano receives infusions of Eisai and Biogen's Alzheimer's drug Leqembi, alongside her service dog Jazmin at the Missouri Baptist Medical Center Infusion Center in St. Louis, Missouri, U.S. October 30, 2023. Joe Castellano/Handout via REUTERS

/ By Julie Steenhuysen

Wu Tsai Neuro and Knight Initiative for Brain Resilience affiliate, Michael Greicius, and others share their expertise on the limitations of the Alzheimer's drug Leqembi.